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Mapping Global Status and Trends in Patent Activity for Biological 
and Genetic Material 
 
PAUL OLDHAM & ANTHONY MARK CUTTER1 
 
Abstract 
 
The extension of intellectual property rights into the realm of biology has emerged as 
an increasing focus of controversy in relation to science,2 biodiversity,3 agriculture,4 
health,5 development,6 human rights7 and trade.8 This paper presents the results of a 
review of international trends in activity for patent protection between 1990-2000 
and provisional data to 2004 and 2005 from over 70 national patent offices, four 
regional patent offices and the World Intellectual Property Organisation (WIPO) 
using the European Patent Office esp@cenet worldwide database.9 The review 
employed patent publication counts as an indicator of activity for traditional 
medicines, pharmaceuticals, agriculture, and biotechnology. The research provides 
insights into the internationalisation of patent activity in multiple areas of biology. 
The review emphasises the need to combine the further development of quantitative 
methods with qualitative analysis of the implications of international patent activity 
in relation to biological and genetic material for science, society and policy.  
 
Introduction 
 
A patent is a legal certificate awarding temporary protection over a claimed 
invention for a period that is at least 20 years.10 During this period, patent holders 
enjoy a range of monopoly rights over the claimed invention including the right to 
exclude others from “making, using, offering for sale, or selling” the invention and 
the associated right to exclude others from “importing” the invention into 
jurisdictions where the patent is in force.11 During the period of protection the patent 
holder may be able to commercially exploit the claimed invention either by bringing 
a product to market or licensing the intellectual property to others.12  
 
Patents have commonly been presented in terms of a bargain between society and 
inventors whereby society accepts the burden of a temporary monopoly to encourage 
innovation and in return inventors disclose new and useful inventions which become 
available to serve the wider public good once the period of protection expires. The 
1990s witnessed the extension of this logic to biological and genetic material on the 
international level.  
 
The internationalisation of patent protection in the realm of biology has been 
justified in terms of the promotion of science and innovation, Foreign Direct 
Investment (FDI), technology transfer and enhanced trade in goods and services.13 In 
the context of the rise of the “knowledge economy” and what is now being called the 
“bioeconomy” the provision of intellectual property protection is increasingly seen as 
central to providing incentives for research and innovation across a spectrum of 
biotechnologies.14 The pursuit of intellectual property in this arena is also being 
promoted among universities as part of a wider process of “turning science into 
business.”15 
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However, the internationalisation of patent protection raises substantive issues 
surrounding the human rights, ethical, social, scientific, economic, environmental 
and legal implications of the extension of particular forms of property and property 
relations into the realm of biology. These concerns range from the human rights of 
indigenous peoples in relation to traditional knowledge and resources,16 the ethics of 
patenting embryonic stem cells,17 the interests of developing countries in relation to 
biodiversity, conservation and development,18 the impacts of patent protection on 
access to affordable medicines,19 innovation in biomedicine,20 the implications of 
processes of “enclosure” for the openness of science21, the future of the public 
domain,22 and the principle of “common heritage.”23 
 
One problem confronting civil society organisations, members of the research 
community and policy makers in debates surrounding intellectual property is the lack 
of visibility of patent activity in relation to biological and genetic material. This 
paper seeks to contribute to addressing that problem and presents the basic results of 
a review of international patent activity across a spectrum of biological and genetic 
material. 
 
Approaching the Patent System 
 
According to statistics compiled by the World Intellectual Property Organisation 
(WIPO), between 1990 and 2000 an estimated 7.6 million patents were granted 
across all areas of invention.24 Calculating the number of patent applications 
worldwide is fraught with difficulty and the available data are unreliable.25 However, 
according to the major patent offices, in the region of 10 million applications are 
estimated to have been submitted by the year 2000.26 The global nature of the patent 
system presents a complex array of methodological obstacles for researchers. 
 
In practice, two main instruments are responsible for the international expansion of 
patent protection over the last decade in the realm of biology. The first of these, 
which has been the subject of extensive scholarly and policy debate, is the 
Agreement on Trade-Related Aspects of Intellectual Property (TRIPS) under the 
World Trade Organisation (WTO).27 For our purposes it is sufficient to highlight that 
the TRIPS agreement extended patent protection to all areas of invention, including 
biology. Specifically, the TRIPS agreement introduced a requirement for member 
states of the WTO to provide patent protection for microorganisms and 
microbiological process and an additional requirement for either patent protection or 
sui generis (of its own kind/specially generated) protection for plants (or both).28 The 
TRIPS agreement provides for the possibility of exclusions from patentability in 
order to “…protect ordre public or morality, including to protect human, animal and 
plant life or health or to avoid serious prejudice to the environment…” (Article 27.2). 
However, these exclusions are limited by the condition that “…such exclusion is not 
made merely because the exploitation is prohibited by their law.” In addition, 
exclusions are possible for “diagnostic, therapeutic and surgical methods for the 
treatment of humans or animals” (Article 27.3 a).29  
 
The second main instrument is the 1970 Patent Cooperation Treaty (PCT) (modified 
2001).30 The Patent Cooperation Treaty introduces a major multiplier effect into the 
international patent system by allowing a single application to be filed for potential 
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protection in up to 133 countries.31 In contrast to the TRIPS agreement, which refers 
to the subject matter of patent protection, the PCT is the main vehicle for the 
internationalisation of patent protection on an operational level.32 The multiplier 
effects of the PCT are accentuated by regional patent instruments such as the 
European Patent Convention and similar arrangements in Africa, the Middle East, 
and Eurasia through which applicants can seek protection in multiple jurisdictions.33 
 
Methodological Foundations 
 
A variety of methods are now available for examining the relationship between 
patent activity and innovation. In particular, the OECD has pioneered the 
development of methods for international comparative analysis ranging through 
patent counts by filing (priority) date,34 the creation of patent families for particular 
country groupings and areas of technology,35 and a framework for the development 
of biotechnology statistics.36 These methods are complemented by additional 
techniques such as the use of patent citation analysis.37 In the arena of biological and 
genetic material, a growing body of work within the scientific journals employs 
combinations of patent counts with qualitative analysis (typically from the United 
States Patent and Trademark Office). However, the development of methods in this 
area is affected by issues of data availability, data comparability, data disclosure and 
the lack of an international contextual framework for analysis of patent activity. 
 
Our research was directly informed by the wider methodological work of the OECD 
in developing an international framework for the analysis of patent activity. 
However, the research was not concerned with the use of patent counts as a measure 
of innovation but focused on the basic question of the identification of biological and 
genetic material within the international patent system in the context of debates 
under the Convention on Biological Diversity. In particular, in view of the scale of 
the international patent system the research was concerned with exploring the 
development of what might be called “open” methods for patent research using a 
data source that is readily accessible to researchers in both developed and developing 
countries. 
 
For this reason the research focused on the identification of biological and genetic 
material (broadly conceived) within the patent system using the freely available 
European Patent Office esp@cenet “worldwide” database.38 While a variety of 
commercial database services are available for patent research these will generally be 
beyond the budgets of most researchers. In contrast esp@cenet is the largest freely 
accessible database of its type and encompasses patent documents from over 70 
countries, 4 regional patent offices and the World Intellectual Property Organisation 
(for the PCT). At the time that research was initiated in 2004 esp@cenet contained 
approximately 48 million patent and related documents. By May 2006 this had 
increased to a reported 54 million patent and related documents.39 As of July 2006 
esp@cenet contained approximately 44.5 million documents that are directly 
concerned with patents.40 esp@cenet is increasingly a focus of efforts to make 
patents in the life sciences more widely available through initiatives such as the 
BIOS Patent Lens developed by CAMBIA in Australia.41 
 
© ESRC Genomics Network.
            Genomics, Society and Policy 
            2006, Vol.2, No.2, pp.62-91 
 
_____________ 
 
Genomics, Society and Policy, Vol.2 No.2 (2006) ISSN: 1746-5354 
65 
In order to identify biological and genetic material within the patent system the 
research focused on the identification of International Patent Classification (IPC) 
codes for biological and genetic material and relevant technology sectors. The IPC is 
a hierarchical classification system of approximately 70,000 alphanumeric codes that 
are used by patent examiners in patent offices around the world to describe the 
contents of patent applications.42 The IPC is the main tool that can be used to identify 
patents relating to biological and genetic material. Thus, patent activity relating to 
traditional medicines can be identified using the codes A61K35/78 or A61K36, while 
activity for genetic engineering for plants can be identified using the code 
C12N15/82. In short, an understanding of classification codes provides a short-cut to 
identifying areas of the patent system relating to biological and genetic material.43 
The IPC also overcomes the difficulties represented by the use of multiple languages 
within the patent system. 
 
For the purposes of the research, a review of the IPC (IPC7 and IPC8) was conducted 
with the aim of identifying the main classifiers and combinations of classifiers 
relevant to biological and genetic material and areas of science and technology.44 
Over 700 classifiers were identified as part of this process.45 In particular, the 
research was concerned with isolating the main areas of the patent system that 
involve direct claims over biological and genetic material. The main classifiers for 
biological and genetic material and sectors of patent activity are provided in Table 
1.46 
 
 
Table 1. Main IPC Classifiers for Biological and Genetic Material 
 
IPC Code Classifiers (Class and Sub-Class Level) 
Section A Human Necessities 
A01 Agriculture 
A01H New plants or processes for obtaining them 
A01K Animal Husbandry…New breeds of animals 
A01N Preservation of Bodies of Animals or Plants or Parts thereof; biocides 
A23 Food or Foodstuffs 
A23L Foods, Foodstuffs, or Non-Alcoholic Beverages 
A61 Medical or Veterinary Science; Hygiene 
A61K Preparations for Medical, Dental or Toilet Purposes 
Section B Transportation 
B82 Nanotechnology 
B82B Nanostructures, Manufacture or treatment thereof 
Section C Chemistry; Metallurgy 
C07  Organic Chemistry 
C07C Acyclic or Carbocyclic compounds 
C07D Heterocyclic compounds 
C07H Sugars; derivatives thereof; nucleosides, nucleotides; nucleic acids 
C07K Peptides 
C08 Organic macromolecular compounds 
C08H Derivatives of natural macromolecular compounds 
C08L Compositions of macromolecular compounds 
C09 Dyes (C09B); Paints (C09D); Natural Resins (C09F); Polishes (C09G); 
Adhesives (C09J); Other Applications (C09K) 
C11 Animal or vegetable oils, fats, fatty substances or waxes 
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C11B Producing, refining preserving fats, fatty substances, waxes 
C11C  Fatty acids from fats, oils, waxes 
C11D  Detergent compositions 
C12 Biochemistry, Beer, Spirits, Wine, Vinegar, Microbiology, Enzymology, 
etc. 
C12N Microorganisms or Enzymes; Compositions thereof…; Mutation or genetic 
engineering… 
C12P Fermentation or Enzyme using processes to synthesise chemical 
compounds 
C12Q Measuring or testing processes involving enzymes or microorganisms 
C12R Indexing classifier for microorganisms & biochemistry. 
C12S Processes using enzymes or microorganisms to liberate, separate or purify 
a compound, to treat textiles or clean solid surfaces 
C40 Combinatorial Technology 
C40B Combinatorial Chemistry; Libraries 
G01 Measuring; Testing 
G01N Investigating or analysing materials by determining their chemical or 
physical properties i.e. for biochemical electrodes 
G06 Computing 
G06F Electrical Digital Data Processing 
 
 
The classifiers and combinations of classifiers were entered into the esp@cenet 
“worldwide” database using the advanced search page to elucidate data on trends in 
activity by patent publication year.47 For areas of patent activity that do not possess 
clear classification codes (i.e. stem cells, genomics, proteomics, bioinformatics) 
additional research was conducted using the commercial whole text Micropatent 
Aureka Gold patent database to identify the main areas of the patent system for these 
emerging areas of activity. 
 
Searches of esp@cenet using IPC indicators and combinations of indicators were 
conducted in 2004 (x 3), 2005 (x 1) and 2006 (x 2). This extensive dataset is made 
available in stand-alone form through this open access journal in order to encourage 
open research methods for patent activity.48 This paper reports on patent activity and 
indicators for ethnobotanicals and traditional medicines, pharmaceuticals, agriculture 
and biotechnologies. Researchers interested in other areas of activity, such as 
biocides, industrial chemistry, microorganisms or other areas will find further 
information in the dataset. In approaching the results presented in this paper it is 
important to emphasise three points.  
 
The use of patent publication counts with esp@cenet has a number of implications 
and limitations when compared with alternative methods. Thus, in contrast with the 
use of patent counts by filing date (priority date) for the purposes of economic 
analysis, patent counts by publication date refer to applications that were filed at 
least 18 months prior to publication. This introduces a significant lag time from the 
perspective of economic analysis. Furthermore, publication data from esp@cenet 
include the original publication of applications and the re-publication of applications 
over time as they move through the patent procedure in multiple jurisdictions on the 
route to becoming patent grants.49 This is a common issue confronting patent 
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research and it is not readily possible to isolate the different types of patent 
publication within the esp@cenet public interface.50 
 
As such, the data do not discriminate between patent applications and grants and 
include data on the movement of applications through the procedure. Here we would 
note that patent applications and patent grants differ in their importance and 
implications.51 The data presented in this paper refer to the overall behaviour of the 
international patent system and encompasses the behaviour of applicants, the 
multiplier effects of international and regional instruments, and the activity of patent 
offices. This has the significant strength of providing an overview of the workings of 
the international patent system on the systemic level in relation to biological and 
genetic material. The increasing use of esp@cenet by national patent offices may 
provide important opportunities for similar analysis of national level trends and 
initiatives such as the BIOS Patent Lens provide increased access to patent 
documents for qualitative analysis. The forthcoming release of the European Patent 
Office Worldwide Patent Statistics Database (PATSTAT) that has been developed as 
part of the Patent Statistics Taskforce led by the OECD should considerably 
strengthen capacity for detailed econometric analysis of patent activity.52 
 
The second point relates to the use of patent databases. The expansion and 
internationalisation of the patent system has led to increasing dependence on the use 
of databases. However, research using patent databases is critically dependent on 
four factors: a) the contents of the database and country coverage; b) the stability of 
the underlying database architecture over time; c) the accuracy of the search 
algorithm, and; d) the behaviour of searchers. 
 
In order to test these issues, the methodology focused on the use of repeat searches of 
esp@cenet in order to generate comparative data over time. This revealed that the 
coverage of the database is expanding over time but that issues surrounding changes 
to the underlying structure of the database, the reclassification of documents and user 
behaviour also need to be borne in mind.53 In general, as we might expect, the repeat 
searches revealed that the data demonstrate significant change in the period closest to 
the present (i.e. 2000-2005) that reflect the addition of documents by patent offices. 
Data for recent years (i.e. 2004 and 2005) will frequently display an apparent steep 
decline in activity. This generally corresponds with a lack of available data.54 The 
numbers provided in this paper thus reflect the status of documentation within 
esp@cenet at the time of the searches. The numbers are approximate in nature and 
intended to serve as indicators of system level trends for particular areas of activity.55 
Data comparability graphs and tables for the main indicators are provided with the 
accompanying dataset. The present article reports on the June 2006 dataset except 
where otherwise stated. 
 
Finally, it is important to note that patent documents are frequently awarded more 
than one classification code in order to adequately describe the claimed invention 
and the contents of applications. This trend will increase under the latest version of 
the IPC (IPC8) which entered into force in January 2006.56 As a consequence, patent 
publications featuring in one area of the data may also appear in other areas of the 
data. However, as we will see, the use of combinations of classifiers provides 
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important opportunities to define sectors of activity and areas of technology in 
relation to biological and genetic material. 
 
Patent Trends for Ethnobotanicals and Traditional Medicines 
 
During the 1990s traditional knowledge of plants and other organisms became an 
important focus of attention in the form of biological prospecting, or 
“bioprospecting,” for new and useful compounds and biological materials in a 
variety of industry sectors, notably pharmaceuticals. 57 Proponents of bioprospecting 
argued that developing countries who are rich in biodiversity would obtain benefits 
through bioprospecting contracts in the form of revenue from milestone payments, 
funding for scientific capacity-building and, potentially, significant royalty streams 
arising from product development.58  
 
However, the rise of bioprospecting rapidly became a focus of controversy. In 
particular, research and patenting involving knowledge and material collected among 
indigenous peoples, local communities and farmers in developing countries led to 
allegations of “biopiracy.”59 This has served to highlight issues surrounding the 
human rights and ethical dimensions of patent activity in relation to the rights of 
indigenous peoples, the extraction and patenting of biological diversity from 
developing countries by individuals, universities and companies in developed 
countries, and the wider implications of intellectual property in relation to biological 
and genetic material. Attempts to address these issues are an important focus of the 
work of the Convention on Biological Diversity and include the potential 
development of one or more new instruments as part of an international regime on 
access to genetic resources and benefit-sharing.60 Developing countries are also 
promoting new instruments under the Intergovernmental Committee on Intellectual 
Property and Genetic Resources, Traditional Knowledge and Folklore (IGC)61 under 
WIPO and amendments to the TRIPS agreement in relation to traditional 
knowledge.62 
 
Growing international debate surrounding traditional knowledge, the human rights of 
indigenous peoples and local communities and the interests of developing countries 
has been accompanied by reports of limited, and declining, interest in natural 
products as a route to drug discovery among pharmaceutical companies.63 Indeed, for 
much of the 1990s it appears that the major pharmaceutical companies focused on 
the apparent promise of synthetic combinatorial chemistry (see below).64 However, 
in practice, what may be called ethnobotanicals and traditional medicines emerged as 
one of the strongest areas of international activity in the review and significantly 
outstrip trends in areas such as agriculture.65 
 
Ethnobotanicals and traditional medicines are mainly situated within “medicinal 
preparations with undetermined constitution” (A61K35).66 In the period 1990-2000 
there were approximately 52,248 publications under “medicinal preparations with 
undetermined constitution” (A61K35), with a provisional 99,339 publications by 
2004 and 114,272 by 2005 (Figure 1).67 This category includes a wide range of 
materials (i.e. from embryos, ovaries, snakes, leeches, algae etc.) but is dominated by 
material from plants (A61K35/78) with 25,803 patent publications recorded between 
1990-2000, 51,060 by 2004 and 60,538 by 2005. 
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Figure 1: Medicinal Preparations with undetermined constitution 
 
 
 
 
Figure 2: Emerging Activity for Ethnobotanicals and Traditional Medicines 
 
 
 
 
Patent publications in relation to plant material are predominantly awarded a single 
classification code by patent examiners. This in part reflects the way in which 
examiners use patent classification codes but also suggests that activity in this area is 
mainly concerned with raw extracts from plants for use as ingredients or partially 
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characterised compounds. However, an insight into the emergence of a range of 
sectors and technologies relating to plants and their components can be gained by 
combining IPC indicators. This is achieved by conducting searches for more than one 
classifier (i.e. A61K35/78 and A61K31) to identify documents that refer to both 
ethnobotanicals and traditional medicines and other areas of activity (i.e. 
pharmaceuticals under A61K31) (Figure 2). An extensive list of such combinations 
for multiple areas of activity is provided in the accompanying dataset as an aid to 
further research.68 
 
The most notable areas of activity in relation to plant material include 
pharmaceutical compounds (A61K31) with 4,609 publications between 1990-2000, 
10,723 by 2004 and 12,347 by 2005. This is followed by foodstuffs (i.e. dietary 
supplements and nutraceuticals under A23L) with 3,728 publications between 1990-
2000, 7,758 to 2004, and 9,147 to 2005. The emerging importance of ethnobotanicals 
in relation to patent activity for cosmetics (A61K7) is reflected in 3,274 publications 
between 1990-2000, 6,094 to 2004 and 6,784 to 2005.  
 
However, Figure 2 also reveals the emergence of patent activity in the realm of 
biotechnology. Thus, 619 patent publications linked to the main indicator for 
biotechnology (C12N) are recorded between 1990–2000, 1,212 by 2004 and 1,338 to 
2005. Indicators are also beginning to emerge for DNA (C07H) with 422 
publications recorded to 2000, 740 publications to 2004 and 848 in the period to 
2005. While the numbers are small relative to wider trends they are suggestive of the 
increasing application of biotechnology related knowledge and techniques to 
ethnobotanicals and traditional medicines.  
 
A striking spike in activity emerges in 2002 in relation to traditional medicines and 
nanotechnology (B82) with a total of 914 patent publications in this area. However, it 
is intriguing to note that one individual, a Yang Mengjun from China, accounts for 
905 of these publications.69 A review of the abstracts for these applications reveals 
that the applicant is listing large numbers of Chinese medicines on the nano scale and 
claiming efficacy in the treatment of disease. Taking into account that these 
applications all appear to have been published on the 11 September 2002 it is 
tempting to conclude that we are confronted with a hyper-inventor. In practice, a 
more likely explanation is that this individual was engaged in speculative patenting 
of traditional medicines on the nano scale with a view to maximising the potential to 
secure licensing revenue (rents) from other actors who may be interested in this area 
of activity. This phenomenon can be described as “biosquatting” and can be 
characterised as exploitation of the availability of monopoly for the purposes of rent 
extraction.70 Biosquatting is similar to the phenomenon of domain name squatting 
that beset the internet in the 1990s.71 
 
The challenging nature of patent activity for ethnobotanicals and traditional 
medicines is also suggested by a detailed review of activity in relation to Lepidium 
meyenii (Peruvian ginseng) which has been a focus of debate surrounding 
biopiracy.72 A review of activity for Lepidium meyenii suggests a tendency for 
applicants, or their lawyers, to seek protection for the components of plants at the 
genus or family level (i.e. Lepidium or Brassicaceae) rather than at the level of an 
individual species.73 This suggests that applicants are seeking to maximise the scope 
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of protection for the claimed invention with a view to maximising opportunities to 
secure rents. However, the nature of patent claims in relation to ethnobotanicals and 
traditional medicines merits much more detailed research. For the present purposes 
this example provides an insight into the growing challenges involved in assessing 
patent activity in the realm of biology. Put simply, the biological components of one 
organism may be shared across species, genera and families of organism (see below). 
 
In the context of international debates under the Convention on Biological Diversity 
and related policy arenas, much attention has focused on the presumed interest of 
major pharmaceutical companies in relation to traditional knowledge. In practice, 
more detailed quantitative research is needed on the structure of international activity 
in relation to ethnobotanicals and traditional medicines. However, preliminary 
research for activity in the main jurisdictions using Micropatent Aureka Gold 
suggests that activity in this area is characterised by a wide range of individuals, 
small companies and public research organisations (PROs) such as universities. 
 
Existing debates about the problem of biopiracy have primarily focused on the 
patenting of traditional knowledge and materials originating from indigenous peoples 
and local communities in developing countries by individuals, universities and 
companies based in developed countries. However, it is interesting to observe that 
individuals, universities and companies from developing countries are becoming 
increasingly active in this area.74 For example, the Council for Scientific and 
Industrial Research (CSIR) in India has been particularly active in patenting.75 The 
most striking example of this is China which accounts for approximately 40% of 
66,434 publications across the database as a whole.76 These patent applications are 
mainly being submitted on the national level but the Chinese authorities are now 
reported to be promoting applications on the international level through the use of the 
Patent Cooperation Treaty.77 
 
Emerging trends in activity for ethnobotanicals and traditional medicines in both 
developed and developing countries raise a variety of issues requiring further 
research. Thus, a clearer assessment is required of patent activity in both developing 
and developed countries in relation to the terms and conditions under which material 
and knowledge is submitted for protection, in relation to the human rights of 
indigenous peoples and local communities, the nature of patent claims, the actors 
involved and the nature of markets. The potential or actual impacts of patent activity 
in the main markets in relation to knowledge and material originating in developing 
countries (i.e. in relation to trade barriers for local producers, also merits further 
research). Finally, the rise of patent activity involving raw extracts raises potential 
issues surrounding the conservation status of the plant and other species involved and 
may merit further research in relation to issues under the Convention on Biological 
Diversity and the Convention on International Trade in Endangered Species of Wild 
Fauna and Flora (CITES).78 
 
In response to growing demand for patent protection for medicinal plant material, a 
new series of classifiers for species and genera have been introduced under indicator 
A61K36 (which replaces A61K35/78 from January 2006). The introduction of these 
classifiers is likely to assist in clarifying the nature of activity in relation to 
ethnobotanicals and traditional medicines. As we will now see, this extends to the 
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need for a better understanding of the transition between traditional medicines and 
pharmaceutical compounds and the wider role of compounds originating in nature in 
the pharmaceutical sector. 
 
Patent Trends for Pharmaceuticals 
 
Patent protection in relation to pharmaceutical compounds is a focus of international 
policy debate in relation to bioprospecting, access to affordable medicines in 
developing countries, and the costs, orientation and performance of the 
pharmaceutical sector in developed countries.79  
 
Pharmaceuticals are located under a variety of classifiers within the patent system 
(Figure 3). The main indicator for pharmaceutical compounds that have been wholly 
or partially characterised is “Medicinal preparations containing organic active 
ingredients” (A61K31). Approximately 332,270 publications are recorded in this 
category between 1990-2000 rising to a provisional 574,386 by 2004 and 637,960 
publications by 2005. With the exception of the activity under organic chemistry, this 
was the main area of international patent activity across the dataset.80  
 
 
Figure 3: Patent Publication Trends for Pharmaceuticals 
 
 
 
 
Patent activity in relation to pharmaceutical compounds can be divided into two 
broad categories. In cases where a new use is claimed for a previously characterised 
compound the application is classified under A61K31 and protection is limited to the 
specific use of the compound. Figure 3 suggests that this remains an important area 
of activity within the patent system. However, where a compound is new, a classifier 
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will also be awarded in the relevant area of chemistry and “per se” (as such) 
protection is provided for the compound during the period of the patent. The data 
reveal that trends in this area are dominated by heterocyclic compounds (C07D) with 
163,092 publications between 1990-2000 rising to 268,570 by 2004 and 295,188 by 
2005. In contrast trends in relation to pharmaceuticals and acyclic or carbocyclic 
compounds (C07C) are less significant with 46,805 publications between 1990-2000, 
72,856 to 2004 and 78,546 to 2005. 
 
Activity in relation to pharmaceuticals begins to enter what appears to be a cross-
over zone between pure chemistry and biotechnology in relation to medicinal 
preparations containing peptides (i.e. short strings of amino acids that form part of a 
protein under A61K38) and preparations containing antigens or antibodies 
(A61K39). This is a cross-over zone in the sense that activity in this area may 
involve pure chemistry and biochemistry and the increasing shift within the 
pharmaceutical sector towards alliances between the major pharmaceutical 
companies and biotechnology companies.81 
 
Figure 3 suggests that trends in activity in relation to peptides and pharmaceutical 
preparations are beginning to catch up with new heterocyclic compounds with 
137,542 publications to 2000, 245,805 publications to 2004 and 266,827 publications 
for peptides to 2005. Patent activity in relation to peptides has led to debate over 
whether biotechnology patents over peptides may stifle research in pure chemistry.82 
 
In the second cross-over category, “medicinal preparations involving antigens or 
antibodies” (A61K39), approximately 61,511 publications are recorded between 
1990-2000, 112,123 by 2004 and 124,267 by 2005. Antibodies (i.e. monoclonal 
antibodies) have emerged as a major focus of activity in relation to biotechnology.83 
There is a strong association between patent activity for peptides and antigens and 
antibodies under peptides (C07K) within organic chemistry.84 As we will see below, 
there is also a strong association between patent activity in relation to peptides, 
antigens and antibodies and areas such as stem cells, genomics, proteomics, and 
bioinformatics. 
 
Patent activity for gene therapy (A61K48) is a discreet area of activity with 22,003 
publications between 1990-2000, 53,379 by 2004 and 59,692 by 2005. This is 
therefore the logical starting point for further research on gene therapy. Patent 
activity for pharmaceuticals and DNA begins to come into focus by combining 
indicator A61K31 with C07H (sugars, nucleotides, nucleosides, nucleic acids) with 
22,012 publications recorded between 1990-2000, 33,409 in the period to 2004 and 
35,984 to 2005. This is followed by the main indicator for biotechnology, 
“microorganisms or enzymes” (C12N), with 13,085 publications between 1990-
2000, 26,201 publications by 2004 and 28,735 in the data to 2005. Activity in this 
area, as we might expect, is dominated by genetic engineering (C12N15) with 20,214 
publications recorded in the data to 2005. 
 
As these multiple indicators suggest, additional research is desirable in order to 
define and disaggregate sectors of activity in relation to pharmaceuticals across the 
spectrum from pure chemistry to biotechnology. However, the basic principle that is 
established here is that it is possible to begin separating out the main areas of 
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international activity through an understanding of patent classifiers and combinations 
of classifiers. Additional information in the dataset may assist in further clarification 
of trends within the pharmaceutical sector. 
 
A further challenge to assessing patent activity in the pharmaceutical sector is 
understanding trends in relation to disease. This is particularly relevant in the case of 
debates surrounding neglected diseases.85 In recognition of the desirability of 
improving indicators in this area, in 2000 a new set of indicators (A61P) were 
introduced for disease categories. A review of the contents of esp@cenet for all years 
across the database within the 2005 dataset revealed the dominance of activity in 
relation to anti-cancer drugs (40,859), treatments for nervous system disorders 
(37,643), anti-infectives (31,939), heart disease (30,145) and disorders of the 
metabolism (23,249). Activity for disease categories of relevance to developing 
countries, i.e. HIV (5,269), antiparasitics (3,905), antiprotozoals for diseases such as 
leishmaniasis, trichomoniasis (963), antimalarials (815) and TB (705) ranked much 
lower. However, it should be noted that these indicators are relatively new and their 
use by patent offices world-wide may be limited. Furthermore, a variety of other 
factors may also affect patent activity in this area.86 In the context of ongoing debates 
relating to intellectual property and pharmaceuticals under the World Health 
Organisation further research is highly desirable in this area.87 Future research would 
ideally combine the use of indicators with the use of whole text databases to test and 
enhance data capture for patent activity and neglected diseases. 
 
Other important areas for clarification relate to the role of compounds from natural 
products in patent activity. Thus, trends in demand for ethnobotanicals and 
traditional medicines would suggest that activity in this area should filter through to 
the main areas of activity for pharmaceutical compounds. However, as Figure 2 
demonstrates, while the trends are significant overall numbers are low. This appears 
to reflect the problem that a linkage between the origin of a compound with a plant 
or other organism within the patent system is not maintained at the level of the 
classification of applications once the compound is characterised or synthesised. 
 
In practice, as Newman, Cragg and Snader (2003) have demonstrated “yet again,” 
compounds originating from, modelled on, or mimicking, natural products are of 
central importance within the pharmaceutical sector at the level of actual approvals 
of new drugs by the United States Food and Drug Administration.88 As Newman, 
Cragg and Snader also highlight, in reviewing approvals between 1981 and 2002, 
they were not able to identify a single de novo combinatorial compound that was 
approved as a new drug during this period.89 In short, debates focusing on the 
promise of de novo combinatorials appear to overestimate their potential and 
underestimate the ongoing importance of natural products at the level of actual 
outputs. This suggests a need for further research on the relationship between 
compounds from nature and pharmaceuticals and international patent activity in the 
context of debates surrounding bioprospecting and access to genetic resources and 
benefit-sharing under the Convention on Biological Diversity. One potentially 
fruitful avenue of enquiry for such research might focus on the nomenclature of 
natural compounds developed by the International Union of Pure and Applied 
Chemistry.90 
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This in turn suggests a need for a wider assessment of the relationship between 
patent protection and outputs in the form of approvals in the pharmaceutical sector. It 
should be emphasised that the data on international trends presented in this paper 
refers to overall publication activity rather than priority applications (first filings) and 
patent grants.91 However, when international trends are viewed in the context of 
declining approvals in countries such as the United States we can perhaps begin to 
legitimately ask the question: where are all the new drugs? 92 That is, bearing in mind 
the complexities of drug development, is the patent system performing its avowed 
function or generating other effects?93 In the context of ongoing international debates 
surrounding the role of patent protection in the pharmaceutical sector, this draws 
attention to the need for closer attention to quantitative analysis of patent activity 
relative to actual outputs in the form of approvals of new drugs.94 Taking into 
account the long lead-in time for the development of new pharmaceuticals, this might 
usefully take the form of country-level studies of patent activity relative to actual 
approvals over a 20-30 year period.95 
 
Patent Trends for Agriculture:  
 
Intellectual property protection for plants takes three main forms: plant variety 
protection, plant patents and industrial patents.96 The present review focuses on 
industrial patent activity (Figure 4). 
 
 
Figure 4: Main Trends for Agriculture 
 
 
 
 
The main indicator for agriculture is “new plants of processes for producing them” 
(A01H). Approximately 23,689 patent publications registered with esp@cenet 
between 1990-2000, 42,371 by 2004 and 46,509 by 2005. Demand in relation to 
agriculture is dominated by the general category of flowering plants (A01H5) with 
approximately 17,455 publications recorded between 1990-2000, 32,210 by 2004 
and 35,100 by 2005. This category includes United States plant patents.97  
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The most striking feature of patent activity in relation to agriculture is growing trends 
towards recombinant genetic engineering for plants (C12N15/82). Between 1990 and 
2000, approximately 15,064 publications emerge in the data, 29,684 by 2004 and 
32,667 by 2005. While Figure 4 suggests that activity is now levelling out, it is also 
interesting to note that patent examiners predominantly award patent applications 
under C12N15/82 rather than both A01H and C12N15/82 (see Figure 4). This 
suggests that further research should concentrate on C12N15/82. Additional 
biotechnology-related indicators include “modification of plant genotypes” (A01H1), 
“plant reproduction by tissue culture techniques” (A01H4) and “undifferentiated 
plant cells and tissues” (C12N5/04). In contrast with biotechnology-related activity 
trends in relation to the modification of plant phenotypes (A01H3) are much lower 
with 416 publications recorded between 1990-2000, 789 to 2004 and 861 to 2005. 
 
The implications of intellectual property protection in the realm of agriculture, 
notably in connection with plant variety protection under the Union for the 
Protection of New Varieties of Plants (UPOV) and debates surrounding patents, 
biotechnology and agriculture in developing countries are a significant focus of 
ongoing public, scientific and policy debate.98 The importance of balancing 
quantitative analysis of patent activity in this area with qualitative analysis of the 
implications of emerging areas of activity such as genomics can be briefly illustrated 
through reference to the rice genome (Oryza sativa).99 
 
In 2001 Syngenta Biotechnology Inc. and Myriad Genetics announced the 
completion of the draft of the rice genome.100 This sparked concern that the genome 
of the world’s major cereal would be patented.101 In response, Syngenta announced 
in 2002 that the genome data would be made available to the publicly funded 
International Rice Genome Sequencing Project.102 However, in 2002 Syngenta also 
submitted a Patent Cooperation Treaty application naming 115 countries entitled 
“Identification and Characterization of Plant Genes” which claimed to have 
identified the genes regulating flowering, head formation and plant morphology in 
rice, wheat, maize and banana (WO03000904). The application described over forty 
species and genera, of which at least 23 are protected under the International Treaty 
on Plant Genetic Resources for Food and Agriculture, as falling within the scope of 
the claimed invention.103 This extended to plants yet to be described by taxonomists: 
“Any other genera or species of Lemmaceae, if they exist, are also aspects of the 
present invention.”104 The specific claims were constructed in terms of the 
percentages of activity of whole or partial DNA and protein molecules, i.e. in 
determining flower meristem identity, such that the discovery and use of 
“substantially similar” or “homologous” DNA and protein molecules from other 
plants for research or product development would infringe the patent. In short, the 
application sought to stake a claim to the fundamental genetic components of 
flowering plants.105 
 
This application was the subject of an unfavourable search report from the European 
Patent Office in relation to prior art in late 2004. In particular, the search report 
identified existing prior art from the University of Washington (US5861542) and 
Max Plank Gesellschaft (WO0037488) in relation to MADS-box proteins for rice, 
grasses and other plants.106 The application also became a focus of an international 
campaign led by the international civil society organisation ETC Group in January 
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2005.107 In February 2005 the company informed ETC that it would allow the 
application to lapse world-wide and the application is now dead.108 However, the 
application formed part of a wider family of applications relating to the rice genome 
that are linked to an underlying patent filing that is 12,529 pages long.109 The patent 
family for the application consists of 23 basic members (as of July 2006) and the 
company is continuing to pursue a small number of applications on specific 
components of the rice genome within this wider patent family.110 Greenpeace, The 
Berne Declaration, No Patents on Life and Swiss Aid are hoping to persuade the 
company to withdraw the remaining applications.111 
 
As this suggests, in considering trends in agricultural biotechnology, the scope of 
patent claims made possible by the mapping of the genomes of organisms may be as 
important as the overall number of patent applications and grants.112 Specifically, 
genomics is dependent upon the identification of genetic similarities (homologies) 
between organisms across species, genera, and classes of organism. Thus, the 
identification of the genetic components of the model plant Arabidopsis thaliana 
which falls into the dicot (dicotyledon) class provided the keys to unlock the genome 
of rice which is a monocot (monocotyledon). This in turn provides the keys to unlock 
the genomes of other major food crops (i.e. wheat, maize etc).113 The reason for this 
is that organisms such as plants are ultimately linked through evolution to common 
ancestors and conserve key elements of their genome over evolutionary time.114 In 
the realm of intellectual property, genomics thus makes possible claims at the level 
of the fundamental common elements of genomes across classes of organism.115 
 
The analysis of the positive and negative implications of patent and related forms of 
intellectual property in the realm of agriculture deserves much greater attention than 
can be provided here. This is particularly true in relation to plant genomics but also 
extends to detailed consideration of biotechnology in relation to animals and 
agriculture. In moving forward with understanding the implications of trends in 
agriculture for plants and animals in both developed and developing countries, this 
suggests the need for closer attention to the development of international indicators 
and combining quantitative analysis with qualitative sampling techniques to generate 
representative data on particular sectors of activity, i.e. plant genomics, 
biotechnology and animals. 
 
Patent Trends for Biotechnology 
 
The discussion in preceding sections illustrates the increasing penetration of 
biotechnologies across a spectrum of sectors of activity and corresponds with 
increasing trends to convergence of science and technology around the “bio”.116 
However, identifying trends in relation to biotechnology as a spectrum of diverse 
sub-sectors of activity encompassing areas such as stem cells, genomics, proteomics, 
bioinformatics, systems biology, bionanotechnology and emerging areas such as 
synthetic biology presents significant challenges. 117 
 
A variety of approaches to analysis of patent activity are emerging in this area. These 
include key word searches of the main patent offices and combinations of classifiers, 
i.e. DNA patents,118 diagnostic testing,119 and sophisticated searches of sequence 
databases for patented sequences as a basis for detailed analysis, i.e. the landscape of 
© ESRC Genomics Network.
            Genomics, Society and Policy 
            2006, Vol.2, No.2, pp.62-91 
 
_____________ 
 
Genomics, Society and Policy, Vol.2 No.2 (2006) ISSN: 1746-5354 
78 
intellectual property for the human genome.120 Taking into account that applications 
from residents of developed countries are the main drivers of patent activity in this 
area, these approaches also provide important insights into wider trends in activity. 
However, in approaching the patent system as a global system, researchers are 
confronted by the use of an increasing number of languages and the lack of 
availability of the whole text of patent documents.121 The identification of key 
indicators for activity is therefore desirable to provide the quantitative context and to 
identify areas for more detailed research. 
 
As a contribution to methodological development, the present research employs a 
provisional IPC based working definition of biotechnology developed by the 
OECD.122 The working definition employs 30 IPC classifiers and indicator C07H for 
DNA was added to improve the data coverage. The results of the searches were then 
ranked to identify the main indicators (Figure 5).  
 
 
Figure 5: Main Trends for Biotechnology 
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Figure 5 reveals that “microorganisms or enzymes” (C12N) is the main indicator for 
patent activity relating to biotechnology with approximately 211,663 publications 
recorded between 1990 and 2000, 390,252 by 2004 and 426,845 by 2005. Trends 
under this indicator are dominated by “mutation or genetic engineering” (C12N15) 
with 142,556 publications to 2000, 268,092 by 2004 and 292,437 by 2005. Other 
strong areas of activity include “measuring or testing processes involving enzymes or 
microorganisms”(C12Q) with 83,077 publications between 1990-2000, 176,530 by 
2004 and 197,612 by 2005. This is followed by “fermentation or enzyme using 
processes to synthesise compounds” (C12P) with 92,322 publications between 1990-
2000, 153,881 by 2004 and 167,008 by 2005. 
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As noted above, the main classifier for DNA is C07H (sugars, derivatives thereof; 
nucleosides, nucleotides and nucleic acids) with approximately 67,942 publications 
recorded between 1990-2000, 124,518 by 2004 and 135,625 by 2005.123 However, it 
appears that this indicator under organic chemistry is now being superseded by the 
use of indicators such as C12N under biochemistry. For this reason, while it remains 
important, an exclusive focus on C07H will underestimate patent activity in relation 
to DNA and biotechnology. Other important areas of activity in relation to 
biotechnology include immunoassays (G01N33/53) in the area of physics with 
25,474 publications between 1990-2000, 55,740 by 2004 and 62,129 by 2005. As 
discussed above, peptides (A61K38 and C07K), antigens and antibodies (A61K39), 
and gene therapy (A61K48) are also very significant areas of activity. 
 
One of the most striking features of patent activity in relation to biotechnology is the 
predominance of patent indicators that refer to microorganisms or enzymes.124 In 
practice, microorganisms are an important focus of interest across a range of research 
and industry sectors and are an increasing focus of bioprospecting activities in areas 
such as Antarctica125 and the deep sea bed.126 The sequencing of the genomes of 
microorganisms (i.e. Archaea and Bacteria) are also a key focus of research 
activity.127 Patent activity in this area now extends to claims to the whole genomes of 
organisms.128  
 
Figure 6 sets out trends in activity relating to microorganisms that have been 
taxonomically described using Bergey’s Manual of Determinative Bacteriology 
(Eighth edition, 1975) under indicator C12R. This reveals approximately 25,062 
publications between 1990-2000, 33,707 publications to 2004 and 34,898 by 2005. In 
practice, the extent to which patent offices consistently use the descriptive indexing 
classier C12R is open to question and the classification system may not be keeping 
pace with patent activity in this important area.129 Further research is desirable on 
this issue. However, it appears reasonable to assume that microorganisms as they are 
ordinarily understood (i.e. Archaea and Bacteria) cannot account for levels of patent 
activity within these areas of the patent system. 
 
 
Figure 6: Patent activity for taxonomically described microorganisms 
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In considering this apparent conundrum it is important to recall that patent activity in 
the realm of biotechnology has its origins in the 1980 United States Supreme Court 
decision Diamond v. Chakrabarty which found that a microorganism that had been 
genetically engineered could be considered to be a product of “human ingenuity” and 
consequently patentable.130 It appears that in the context of the subsequent expansion 
of patent activity in the realm of biotechnology, the categories of the patent system 
that relate to microorganisms and enzymes have been converted into catch-all 
categories for a wide range of biological and genetic material. This also serves to 
highlight the wider significance of the requirement within the TRIPS agreement that 
patent protection must be provided for microorganisms and microbiological 
processes.131  
 
Thus, the guidance notes for the Biochemistry class (C12), within which C12N and 
the other major indicators are located, explains that: “In this class, viruses, 
undifferentiated human, animal or plant cells, protozoa, tissues and unicellular algae 
are considered as micro-organisms”.132 In the case of “undifferentiated human, 
animal or plant cells” this extends to stem cells and plant meristems, tissues, cell 
lines and culture media (Figure 7).133 
 
 
Figure 7: Undifferentiated Human, Animal or Plant Cells or Tissues 
 
 
 
 
The main indicator for undifferentiated human, animal and plant cells or tissues is 
C12N5. A total of 53,885 publications were recorded between 1990-2000, 109,234 
by 2004 and 119,525 by 2005 (not shown). In practice, on the international level 
patent offices classify at different levels of detail and the use of C12N5 appears to 
predominate. However, Figure 7 reveals significant activity in relation to 
undifferentiated animal cells or tissues (C12N5/06) with 9,139 publications recorded 
between 1990-2000, 28,771 by 2004 and 31,965 by 2005. In the case of 
undifferentiated human cells or tissues (C12N/08) 4,984 publications were recorded 
between 1990-2000, 12,226 by 2004 and 14,195 by 2005. Activity in relation to 
plants (C12N5/04) registered 3,109 publications between 1990-2000, 6,244 by 2004 
and 7,002 by 2005. 
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Patent activity in relation to undifferentiated animals cells or tissues (C12N/06) 
encompasses embryonic stem cells such as the University of Wisconsin Alumni 
Research Foundation (WARF) patent applications and grants on primate embryonic 
stem cells arising from research with marmosets and rhesus monkeys (i.e. 
WO9622362).134 These patent applications were constructed in such a way that 
claims relating to embryonic stem cells in rhesus monkeys and marmosets extended 
to primates and thus to humans. As in the case of genomics, this exposes the issue 
that patent claims may be constructed to encompass homologous material in other 
organisms.135 These patent grants are a significant focus of debate within the 
literature.136 Looking beyond the substantive ethical debates that revolve around 
embryonic stem cell research and patenting, this exposes the difficulties presented 
for scientific research by expansive claims across organisms.137 
 
Patent activity in relation to stem cell related indicators also provides an insight into 
areas such as cloning.138 Thus, Patent Cooperation Treaty applications submitted by 
former Seoul National University Professor Hwang Woo Suk and colleagues in 
relation to an embryonic stem cell line (WO2005063972), a transgenic cloned cow 
(WO2004016773), a cloned pig (WO03089632), a method for producing a cloned 
tiger through inter-species nuclear transfer (WO0100794) and the same methods for 
producing a cloned human embryo (WO0100793) are classified under C12N5 but 
may also cross-link to “mutation or genetic engineering” (C12N15) and new breeds 
of animals under agriculture (A01K).  
 
Hwang Woo Suk and his colleagues published two articles relating to cloning and 
stem cell research in the journal Science. These papers, Evidence of a Pluripotent 
Human Embryonic Stem Cell Line Derived from a Cloned Blastocyst
139 and Patient-
Specific Embryonic Stem Cells Derived from Human SCNT Blastocysts
140 have been 
the subject of much media discussion, and have been retracted by the journal’s 
editors141. The investigating committee of Seoul National University (SNU) 
concluded that the data and claims presented in relation to stem cells lines were 
fabricated.142 In addition to the legal and ethical issues raised by this level of alleged 
scientific misconduct, this raises questions about the technical validity of the 
inventions claimed within the patent applications. The wider implications of 
scientific misconduct for the international intellectual property regime in areas of 
‘breakthrough’ science merit fuller consideration than can be provided here. 
However, ongoing controversies about patent applications arising from this research 
suggest a need to question the role of intellectual property in ‘turning science into 
business’ in such sensitive areas.143  
 
For our present purposes the important point here is that we now have a clearer idea 
where to begin looking for patent activity in relation to stem cells and cloning. 
However, stem cell-related patent activity also introduces the wider methodological 
challenge that new areas of science and technology do not necessarily fall into single 
areas of the patent system. As a contribution to further methodological development, 
research was conducted using the Micropatent Aureka Gold patent service in order to 
begin defining the main areas of patent activity for stem cells, genomics, proteomics, 
and bioinformatics. The searches were confined to United States applications and 
grants, European Patent Convention applications and grants, PCT applications, 
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applications and grants for Germany, and applications for the UK, Japan and France. 
The searches covered the period from 1 January 1990 to 31 December 2005. 
 
A search of the main jurisdictions using the Micropatent Aureka Gold whole text 
service for the simple terms “stem cell or pluripotent or totipotent” revealed a raw 
sample of 32,490 documents.144 Of these 25,458 (78%) were published between 1 
January 2001 and 31 December 2005. Refinement of the search terms may be 
desirable to enhance data capture. However, this example serves to suggest a 
dramatic increase in patent activity in the main jurisdictions and is mirrored in areas 
such as genomics (see below).  
 
A total of 20,458 (63%) of these publications were classified under C12N for 
microorganisms or enzymes. On a more detailed level of the 32,490 documents a 
total of 12,676 (39%) were classified under C12N5 (for undifferentiated material) 
while 11,283 (35%) were classified under C12N15 (for genetic engineering). Taken 
together these two indicators accounted for 19,040 (59%) of the overall sample and 
93% of documents under C12N and confirms that this is the logical starting point for 
research.145 However, the research also revealed that documents are classified under 
10 main IPC classifiers ranging from agriculture, to pharmaceuticals, and physics. In 
total the 10 classifiers encompassed 31,423 documents (97%) of patent activity for 
the sample. However, 64 classifiers are required to reach 99.68% and some 
documents go unclassified. 
 
In the case of genomics, a total of 128,400 publications containing the term 
“genome” were published in the main jurisdictions between 1990-2005.146 Of these, 
39,542 documents were published between 1990 and the end of 2000 while 88,858 
documents (69%) were published between 2001 and the end of 2005. As this makes 
clear, patent activity in relation to genomics has undergone dramatic expansion in 
recent years and corresponds with the completion of the maps of the human genome 
and the first genomes of plants (i.e. Arabidopsis thaliana and Oryza sativa), animals, 
insects and microorganisms.147  
 
A sample of 50,454 documents published between 2001 and 2003 containing the 
term genome was analysed in order to identify the main classifiers relating to 
genomics. This revealed that 32,476 (64%) of the sample falls within C12N. Other 
significant areas include C12Q (36%) C12P (26%) and C07H (29%). Combined, 
these four indicators capture 41,755 (83%) of genome related publications. As noted 
in the discussion of pharmaceuticals, indicators for peptides (A61K38 and C07K), 
antigens and antibodies (A61K39) and gene therapy (A61K48) are also significant in 
this area. Coverage improves to 47,810 (95%) through the inclusion of medicinal 
preparations (A61K) and peptides (C07K). However, patent activity in relation to 
genomics also reveals the importance of activity falling in the area of physics within 
the international patent classification. Thus, a total of 14,591 documents in the 
sample are awarded classifiers in relation to “investigating or analysing materials by 
determining their chemical or physical properties” (G01N) and “electrical digital 
data processing” (G06F). When these indicators are included data capture increases 
to 48,364 (96%) of the sample. Data capture can be increased to 99.93% by using 65 
classifiers but becomes increasingly fragmentary. 
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The increasing importance of activity classified under physics is also revealed in 
relation to proteomics and bioinformatics. Here we should emphasise that further 
research is required on the extent to which activity under physics involves per se 
claims over biological and genetic material. 
 
For proteomics (the protein complement of a cell or organism) a search of the main 
jurisdictions for the term proteome revealed 3,671 publications between 1990 and the 
end of 2005. Of these 3,544 (96%) were published from 2001 onwards. The main 
indicator for proteomics is “investigating or analysing materials by determining their 
chemical or physical properties” (G01N) which accounts for 2,159 (59%) of 
documents in the sample i.e. mass spectrometry. This is followed by “measuring or 
testing processes involving enzymes or microorganisms” (C12Q) with 1,499 (41%) 
of the sample. When combined these indicators account for 2,758 (75%) of the 
sample. Other important areas of activity include peptides (C07K and A61K38) and 
C12N which push data capture to 3,351 (91%). Data capture can be enhanced to 
3,587 (98%) through the addition of DNA (C07H), and pharmaceuticals (under 
A61K notably, antigens and antibodies, gene therapy), “digital data processing” 
(G06F), “apparatus and separation” (B01D) and “electric discharge tubes/lamps” 
(H01J). 100% of proteome related activity can be captured using 36 classifiers. 
 
In the case of bioinformatics, a total of 9,567 documents were published in the main 
jurisdictions between 1990-2005 containing the term “bioinformatics” of which 
8,855 (93%) were published since 2001. Activity in this area is dispersed across 
C12N (52%), peptides (under C07K) with 48%, C12Q (42%) and G01N (35%) and 
G06F for digital data processing (16%). Taken together these five indicators 
encompass 9,094 (95%) of activity. Data capture to 99.6% was achieved using 35 
classifiers but became increasingly fragmentary. 
 
These examples serve to demonstrate that it is possible to capture the main indicators 
for particular areas of activity as a basis for further research. However, problems of 
fragmentation also begin to emerge in demarcating areas of activity beyond 
approximately 95%. This reflects the dispersal of activity across a range of sectors. 
This problem has proved to be particularly marked in the case of nanotechnology 
which has undergone dramatic expansion in recent years.148 In response, indicators 
for nanotechnology were introduced into the IPC (i.e. B82 and A61K9/51). However 
the pace of the ‘nano rush’ proved such that the USPTO introduced classifier 977 
and the European Patent Office introduced a “tag” Y01N into esp@cenet documents 
under the European Patent Classification (ECLA). This can now be used to identify 
bionanotechnology patents i.e. Y01N and C12N produced 1,245 results in esp@cenet 
at the time of writing. Similar challenges may also emerge in relation to systems 
biology149 and synthetic biology.150 
 
Conclusions 
 
This article has set out the basic results of a review of international patent activity in 
relation to biological and genetic material and provided suggestions for further 
research. In making the accompanying dataset available through an open access 
journal our aim has been to encourage the development of open research methods 
that will provide researchers, civil society organisations and policy makers in both 
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developed and developing countries with a “clearer view” of patent activity in 
relation to biological and genetic material.151 
 
As we have seen there are considerable challenges involved in addressing the 
international scale of patent activity for biological and genetic material and assessing 
the implications for science, society and policy. Addressing these challenges merits 
much greater attention from the research community. In particular, this research has 
demonstrated that biological and genetic material now occupies an increasingly 
prominent position within the international patent system. Patent activity in relation 
to biological and genetic material ranges from crude extracts from plants for use as 
ingredients in foodstuffs, medicines and cosmetics to pharmaceutical and industrial 
compounds, DNA and proteins, microorganisms, the genomes of organisms and their 
components and stem cells. Increasingly, activity is also moving into areas such as 
proteomics, bioinformatics, bionanotechnology, systems biology and synthetic 
biology. 
 
The recent work of the OECD and the Patent Statistics Task Force in developing an 
international framework for statistical analysis and the new European Patent Office 
World Patent Statistics Database will greatly facilitate statistical analysis. However, 
it is also important to recognise that the characteristics and implications of activity in 
one area of the patent system (i.e. traditional medicines) will not be the same as those 
in other areas of the patent system (i.e. genomics or synthetic biology).152 As we 
have argued in this paper, there is a need for a better understanding of the 
characteristics of sectors of activity and the actors and the markets involved as a 
basis for assessing their implications for science, society and policy. 
 
When viewed from an international perspective this raises the challenge of how a 
structured approach might be developed that simultaneously recognises the scale and 
diversity of patent activity and the need for quantitative and qualitative analysis. In 
particular, how might international collaboration and data comparability be promoted 
in this area? 
 
One answer to this question is to structure research around the International Patent 
Classification system. As the accompanying dataset reveals, in practice, the IPC 
operates at a considerable level of detail in relation to the type of material. This 
provides researchers with opportunities to target specific areas of activity and to 
situate their research within a wider context that can be linked with quantitative 
analysis.153 Here it may be noted that areas such as genomics, systems biology and 
synthetic biology present complex methodological issues at the level of indicators. 
However, as existing research and the present paper highlights, it is possible to begin 
demarcating these areas as a basis for detailed research. In short, a structured 
approach to research that is linked to the IPC will provide a basis for the international 
comparability of research efforts on a variety of levels. Tools such as esp@cenet and 
the BIOS Patent Lens also provide researchers from both developed and developing 
countries with important free resources through which to interrogate the patent 
system in a structured way. This may then be linked with the use of sophisticated 
quantitative research tools. 
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Finally, as noted in the introduction to this paper, the internationalisation of patent 
protection in the realm of biological and genetic material raises substantive issues 
across a spectrum from human rights and ethics to the future of science, innovation 
and world trade. In practice, the identification of the main indicators for biological 
and genetic material within the international patent system provides opportunities for 
targeted international policy responses. These opportunities include the potential 
introduction of new and more “open” models that recognise international concerns 
and promote the sharing of knowledge and resources to serve the wider public good. 
The exploration of those opportunities will be the focus of our future research. 
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